Anlotinib Hydrochloride Capsule Clinical Trials

4 actively recruiting trials

Also known as: Anlotinib

Pipeline

Phase 2: 2Phase 4: 1

Top Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2
The First Affiliated Hospital with Nanjing Medical University1
Ji Yongling1

Indications

Cancer4
Medullary Thyroid Cancer1
Gastrointestinal Diseases1
Digestive System Diseases1
Thyroid Neoplasms1

Other4 trials

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Phase 2

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Phase 4

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.